Abstract
OBJECTIVE: To determine change in SAGE scores over time in individuals with various clinical diagnoses. BACKGROUND: SAGE is a valid self-administered cognitive assessment tool for detecting cognitive impairment including MCI and mild dementia. DESIGN/METHODS: Retrospective chart review from October 2005 through August 2014 was performed on consecutive subjects seen in the Memory Disorders Clinic at Ohio State University who had at least 2 SAGE tests done at least 6 months apart. Additional neuropsychological testing (CERAD battery) performed in all subjects was the sole basis of determination of normal or impaired cognition. Individuals with normal cognition despite cognitive complaints and basically no deficits in Activities of Daily Living (ADL) were classified as SCI. Individuals with mildly impaired cognition and no or minimal decline in ADL were classified as MCI. MCI individuals who developed, over time, significantly impaired cognition and decline in ADL sufficient to meet criteria for dementia were classified as Converters. AD patients met the diagnostic criteria of DSM-IV and NINCDS-ADRDA. One way and repeated measures ANOVAs were preformed. RESULTS: 440 individuals (46 SCI, 98 MCI non-converters, 70 Converters, 226 AD) met the inclusion criteria. Baseline mean SAGE scores (out of 22) for SCI (19.7±2.0) was significantly different than MCI non-converters (17.1±3.3), Converters (16.5±3.1), and AD (10.7±4.7) groups. However, baseline SAGE scores were not significantly different for the MCI non-converter and Converter groups. SAGE scores declined significantly over time (p<0.0001) for Converters (-1.97 points/year) and AD (-1.79 points/year) but not for SCI (0.10 points/year) or MCI non-converters (0.03 point/year) (p>0.05). CONCLUSIONS: SAGE scores were stable over time in SCI and MCI who did not convert to dementia. Those with declining SAGE scores were at high risk for dementia diagnosis. The ease of repetitively giving the self-administered SAGE and identification of score stability or decline may provide clinicians significant diagnostic assistance.
Disclosure: Dr. Scharre has received personal compensation for activities with Eli Lilly & Company as a consultant. Dr. Chang has received research support from the Harry T. Mangurian Jr. Foundation. Dr. Nagaraja has received research support from the Mangurian Foundation. Dr. Kataki has received research support from Pfizer Inc., Lundbeck Research USA, Inc., Merck, Avinar Pharmaceuticals, Eli Lilly & Co., EnVivo Pharmaceuticals, AstraZeneca, Phylogeny, Inc. and the Harry T. Mangurian Jr. Foundation. Dr. Wheeler has nothing to disclose. Dr. Adeli has received research support from Pfizer, Lundbeck, Avanir, Merck, Eli Lillly, Envivo, and AstraZeneca.
Wednesday, April 22 2015, 7:30 am-12:00 pm
- Copyright © 2015 by AAN Enterprises, Inc.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
